Eisuke Murakami
Overview
Explore the profile of Eisuke Murakami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
2525
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagaoki Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, et al.
Therap Adv Gastroenterol
. 2025 Mar;
18:17562848251324094.
PMID: 40078327
Background: It is not clear that antiviral therapy for hepatitis C virus (HCV) after recovery from curative treatment for hepatocellular carcinoma (HCC) has an effect on suppressing recurrence or improving...
2.
Nakahara H, Ono A, Hayes C, Shirane Y, Miura R, Fujii Y, et al.
J Proteome Res
. 2025 Feb;
24(3):1102-1117.
PMID: 39982271
Chronic liver diseases exhibit diverse backgrounds, and it is believed that numerous factors contribute to progression to cancer. To achieve effective prevention of nonviral hepatocellular carcinoma, it is imperative to...
3.
Kosaka M, Fujino H, Tsuge M, Yamaoka K, Fujii Y, Uchikawa S, et al.
J Gastroenterol
. 2025 Jan;
PMID: 39841247
Background: Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the...
4.
Nakahara H, Ono A, Hayes C, Shirane Y, Miura R, Fujii Y, et al.
JCO Clin Cancer Inform
. 2024 Dec;
8:e2400108.
PMID: 39693579
Purpose: Postsustained virologic response (SVR) screening following clinical guidelines does not address individual risk of hepatocellular carcinoma (HCC). Our aim is to provide tailored screening for patients using machine learning...
5.
Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, et al.
J Gastroenterol
. 2024 Dec;
60(3):328-339.
PMID: 39652104
Background: This study aims to identify biomarkers for treatment response of atezolizumab plus bevacizumab (Atezo+Bev) in patients with hepatocellular carcinoma (HCC). Methods: 96 patients who received Atezo+Bev or lenvatinib as...
6.
Bao H, Murakami S, Tsuge M, Uchida T, Uchikawa S, Fujino H, et al.
Viruses
. 2024 Nov;
16(11).
PMID: 39599858
Cross-sectional analyses using liver tissue from chronic hepatitis B patients make it difficult to exclude the influence of host immune responses. In this study, we performed next-generation sequencing using the...
7.
Fujii Y, Kawaoka T, Shirane Y, Miura R, Nakahara H, Yamaoka K, et al.
Oncology
. 2024 Nov;
:1-6.
PMID: 39527933
Introduction: Durvalumab plus tremelimumab combination therapy (STRIDE regimen) is a new first-line option for unresectable hepatocellular carcinoma (uHCC), but little real-world data are available to determine which patients are most...
8.
Uchikawa S, Kawaoka T, Murakami S, Miura R, Shirane Y, Johira Y, et al.
Hepatol Res
. 2024 Oct;
PMID: 39460960
Background: We have been able to use molecular targeted agents for unresectable hepatocellular carcinoma since 2009, and immune checkpoint inhibitors have been approved in recent years. We assessed the efficacy...
9.
Tanaka A, Kawaoka T, Uchikawa S, Fujino H, Ono A, Murakami E, et al.
Clin J Gastroenterol
. 2024 Oct;
18(1):107-113.
PMID: 39446307
A 58-year-old man visited an orthopedic clinic complaining of pain in his right lower back and numbness in his lower limbs for one month. Imaging tests revealed a tumorous lesion...
10.
Miura R, Ono A, Yano S, Amioka K, Naruto K, Yamaoka K, et al.
Medicine (Baltimore)
. 2024 Sep;
103(34):e39289.
PMID: 39288227
The efficacy and safety of immune-checkpoint inhibitors (ICI) for the treatment of unresectable hepatocellular carcinoma are known. We explored ICI rechallenges with direct switching from 1 ICI regimen to another....